Shares of ImmuPharma plc (LON:IMM – Get Free Report) traded up 30.9% during trading on Tuesday . The company traded as high as GBX 7.30 ($0.09) and last traded at GBX 7.20 ($0.09). 53,237,734 shares were traded during mid-day trading, an increase of 131% from the average session volume of 23,020,018 shares. The stock had previously closed at GBX 5.50 ($0.07).
ImmuPharma Stock Performance
The company has a market capitalization of £18.41 million, a price-to-earnings ratio of -442.00 and a beta of 1.53. The business’s 50 day moving average is GBX 1.98 and its 200 day moving average is GBX 1.80.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Read More
- Five stocks we like better than ImmuPharma
- Compound Interest and Why It Matters When Investing
- Coinbase Gains Momentum on App Store—What It Means for the Stock
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- How to Short Sell Stocks Like a Pro: Strategies and Tips
- Why Invest in High-Yield Dividend Stocks?
- 3 Steel Stocks Soaring After Tariff Announcements
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
